Ribo’s siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia

On October 28, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the lipid-lowering siRNA drug RBD5044 that targets APOC3. The trial will evaluate efficacy and safety in patients with mixed dyslipidemia.

A randomized, double-blind, placebo-controlled, multi-center phase II trial evaluating the efficacy and safety of RBD5044 in participants with mixed dyslipidemia will be run. The trial sites include Ribocure Clinic, a specialized phase II unit for high quality functional imaging proof of principle trials, based in GoCo Health Innovation City, Gothenburg, as well as sites in Lund and Uppsala, Sweden.

RBD5044 is a GalNAc-conjugated small interfering RNA (siRNA) drug based on the RIBO-GalSTARTM liver targeting technology platform. The inhibition of APOC3 by siRNA-mediated knockdown is a highly potent, high precision and long-lasting mechanism to reduce plasma levels of atherogenic ApoC-III containing triglyceride-rich particles.

Plasma ApoC3 levels predict coronary events independently of LDL cholesterol values. In addition, genetic studies demonstrate that APOC3 Loss-Of-Function mutations are associated with lower plasma triglycerides and about a 40% lower risk of cardiovascular disease. Thereby, RBD5044 has the potential to reduce residual cardiovascular disease by targeting a lipid-related risk that is not amenable to current lipid-lowering therapies. In patients with severe hypertriglyceridemia, the inhibition of ApoC-III and lowering of plasma triglyceride levels might also reduce recurrent pancreatitis events.

RBD5044 is the second siRNA targeting APOC3 world-wide to enter clinical stage. Based on Ph1 safety and efficacy data, we are optimistic about the potential of RBD5044 to be best-in-class in treating mixed dyslipidemia and isolated hypertriglyceridemia. “Hypertriglyceridemia, both in fasting and postprandial states, has been shown to be closely linked to residual cardiovascular risk and currently lacks an effective therapeutic option. We are committed to accelerating the development of RBD5044 to address this significant unmet clinical need. The approval marks our fourth clinical trial authorization in 2024, a milestone that reflects our dedication to advancing oligonucleotide therapeutics. I am incredibly proud of our team, which has consistently shown its ability to not only develop efficacious and safe siRNAs, but also navigating the regulatory landscapes with speed and precision”, says Li-Ming Gan, CEO of Ribocure.

Share on social media

Recommended articles

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website, www.ribocure.com.
 
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
 
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
 
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
 
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
 
Contact information to the Data Protection Officer (DPO):
 
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal
Sweden
 
E-mail: dpo@ribocure.com